Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
Ann Rheum Dis
; 79(6): 724-726, 2020 06.
Article
in English
| MEDLINE | ID: covidwho-155085
ABSTRACT
Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Scleroderma, Systemic
/
Coronavirus Infections
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Ann Rheum Dis
Year:
2020
Document Type:
Article
Affiliation country:
Annrheumdis-2020-217407
Similar
MEDLINE
...
LILACS
LIS